Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

Abstract:
A needle-free vaccine platform that elicits a robust immune response against a wide array of viruses and bacteria has been awarded a U.S. patent. The University of Michigan holds the patent and NanoBio Corporation, a spin-off from the university, licenses the patent and its associated technology.

New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

ANN ARBOR, MI | Posted on January 30th, 2008

The intranasal vaccines, produced using NanoBio's nanoemulsion technology, have elicited a dramatic immune response in animals vaccinated against influenza, anthrax, hepatitis B and other diseases. In some cases, the immune response is exponentially higher than what is required to provide adequate protection against infection. Such dramatic levels of immunity would confer significantly higher levels of protection to the vaccinated population at large compared with current injectable vaccines.

Because the vaccines trigger such robust immunity, scientists anticipate they will be able to reduce vaccine antigen quantities to a fraction of what current vaccines require, while still mounting an overwhelming immune response.

This "antigen-sparing" capability would enable scientists to rapidly produce large quantities of vaccines using miniscule amounts of antigen, a critical factor when faced with a disease pandemic or biological warfare.

"We have shown that when we mix our nanoemulsion with whole virus or a recombinant protein antigen and apply it to the naso-pharynx, the resulting vaccine elicits strong mucosal and systemic immunity," said James R. Baker Jr., M.D., founder and Chairman of NanoBio Corporation. "The nanoemulsion serves as an adjuvant to boost immune response against a specific antigen."

NanoBio is in various stages of testing its extensive pipeline of mucosal vaccines for influenza, bird flu, hepatitis B, HIV, RSV, small pox, anthrax and other viral and bacterial infections. Final results from the influenza vaccine study in ferrets are expected this quarter, and human tests with the influenza and hepatitis B vaccines are being planned.

The newly awarded patent covers the methods and compositions of formulating nanoemulsion vaccines, a unique coupling of oil, water, and antimicrobial surfactant together with antigens from specific pathogens.

Studies in animals demonstrate these vaccines easily penetrate the mucous membrane, where dendritic cells rapidly engulf the antigen and present it to the immune system. This rapid awakening of the immune system via the intranasal route negates the need for inflammatory stimulants used in traditional vaccines, which can cause pain and swelling at the site of vaccination, said Dr. Baker.

"We present antigen in an optimal location where it can most directly access the immune system," added Baker. "As a result, there is no need to prime the immune system with immunostimulants in order to provoke its recognition of the antigens."

Moreover, the vaccine requires no harsh chemicals to attenuate the whole virus and render it harmless, because the nanoemulsion itself kills the antigen. Advantages of the nanoemulsion vaccines include:

-- nasal delivery, the entry point of most respiratory infections -- development of rapid mucosal immunity followed by systemic immunity -- antigen-sparing capability -- thermally stable, requires no refrigeration -- needle-free, easy to administer

The development of the nanoemulsion platform began in 1998 and is supported, in part, by a $6.3 million grant from the Bill and Melinda Gates Foundation to the Michigan Nanotechnology Institute for Medicine and Biological Sciences, which is led by Dr. Baker. The new patent for nanoemulsion vaccines (#7,314,624 B2) is licensed to NanoBio Corporation on an exclusive, worldwide basis. With this new patent, NanoBio now holds five U.S. patents and has filed numerous additional applications in various jurisdictions.

####

About NanoBio Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

Address:2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Doubling down on Schrödinger's cat May 27th, 2016

Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016

Nanomedicine

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Nanoscale Trojan horses treat inflammation May 24th, 2016

Announcements

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Doubling down on Schrödinger's cat May 27th, 2016

Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016

Patents/IP/Tech Transfer/Licensing

Programmable materials find strength in molecular repetition May 23rd, 2016

Syracuse University chemists add color to chemical reactions: Chemists in the College of Arts and Sciences have come up with an innovative new way to visualize and monitor chemical reactions in real time May 19th, 2016

Researchers integrate diamond/boron nitride crystalline layers for high-power devices May 12th, 2016

New tool allows scientists to visualize 'nanoscale' processes May 4th, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Finding a new formula for concrete: Researchers look to bones and shells as blueprints for stronger, more durable concrete May 26th, 2016

Light can 'heal' defects in new solar cell materials: Defects in some new electronic materials can be removed by making ions move under illumination May 24th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic